CVR 43055909Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)Ole Maaløes Vej 3, 2200 København NFounded 14 Feb 2022
Ousia Pharma ApS
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Ousia Pharma ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
5
CVR, Aug 2026
-1 (-16.7%) over 12 months
Gross profit
-10.2M
DKK, annual report 2025
Result
-12.8M
DKK, annual report 2025
Equity
11.8M
DKK, annual report 2025
JLSa2 Therapeutics, Inc.100% of capital and votes
Operating company
Dandex estimate: 5 employees registered in 2026Christoffer Clemmensensince 14 Feb 2022
Jonas Odgaard Petersensince 14 Feb 2022
Anders Bue Kleinsince 14 Feb 2022
Owners of 5% or more. CVR registers shares in bands, not exact figures.
100% of capital and votessince 31 Jul 2026
CVR 410598505% to under 10% of capital and votesclass Ordinære kapitalandelenotified 31 Jul 202611 Jun 2025 to 31 Jul 2026
CVR 4189866610% to under 15% of capital and votesclass Ordinære kapitalandelenotified 11 Jun 202527 Mar 2025 to 11 Jun 2025
CVR 4292633710% to under 15% of capital and votesclass Ordinære kapitalandelenotified 31 Jul 202614 Feb 2022 to 31 Jul 2026
CVR 4295499310% to under 15% of capital and votesclass Ordinære kapitalandelenotified 31 Jul 202614 Feb 2022 to 31 Jul 2026
CVR 4301326210% to under 15% of capital and votesclass Ordinære kapitalandelenotified 31 Jul 202614 Feb 2022 to 31 Jul 2026
33.3% to under 50% of capital and votesclass Bnotified 31 Jul 202627 Mar 2025 to 31 Jul 2026
Founded 14 Feb 2022.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Aug 2026, monthly: 5 employees, 4 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 7 | 6 | 6 | 7 | 6 | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 3 | 3 | 3 | 4 | 6 | 6 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 5 |
| FTE | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 4 | 6 | 5 | 7 | 7 | 6 | 7 | 7 | 7 | 7 | 7 | 6 | 7 | 4 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit -10.2M, Operating profit -14.4M, Result for the year -12.8M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 12.5M, Equity 11.8M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Gross profit | -645 | -2,240 | -3,656 | -10,205 |
| Operating profit | -1,095 | -4,304 | -5,672 | -14,414 |
| Result for the year | -904 | -3,747 | -5,349 | -12,778 |
| Equity | -864 | -4,738 | -10,087 | 11,818 |
| Total assets | 3,280 | 5,798 | 5,090 | 12,498 |
| Employees (average) | 3 | 5 | 6 | 8 |
Not every period is a full year: 2022 covers 11 months (14 Feb to 31 Dec 2022). Changes against it compare periods of different length.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCash, debt conversionPaid in 26,163,278 | None | 26,163,278 | None | 99,583 | |
| IncreaseDebt conversion, cashPaid in 34,682,858, cash price 1,607.44, implied value 99,495,509 | 1,607.44 | 34,682,858 | 99,495,509 | 61,897 | |
| FoundingCashPaid in 40,002 | None | 40,002 | None | 40,002 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | |||
| Employee growth (vækst i antal ansatte) | Not reportednote 1 | 66.7% | 20% | 33.3% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | |||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | |||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | |||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | |||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | |||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | |||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | |||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Source: CVR, read 19 Nov 2026.
8 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Vedtægterne er yderligere ændret
Vedtægter ændret: 31.07.2026
Bestyrelse:
Fratrådte:
Christoffer Clemmensen, den 31.07.2026, Founder Ian Rodney Laquian, (formand), den 31.07.2026, Margareta Elisabeth Björk, den 31.07.2026.
Tiltrådte:
Gaurav Gupta, (formand), den 31.07.2026, Ramesh Rajanikant Bhatt, den 31.07.2026.
Vedtægter ændret: 31.07.2026
Kapitalforhøjelsen er besluttet den 31.07.2026.
kr. 851,00, indbetalt kontant, kurs 100,00. kr. 36.835,00, indbetalt ved konvertering af gæld, kurs 71.026,00.
Kapitalen udgør herefter kr. 99.583,00.
Vedtægter ændret: 11.06.2025
Vedtægter ændret: 07.05.2025
Vedtægter ændret: 27.03.2025
Kapitalforhøjelsen er besluttet den 27.03.2025.
kr. 9.645,00, indbetalt ved konvertering af gæld, kurs 155.435,55. kr. 12.250,00, indbetalt kontant, kurs 160.743,67.
Kapitalen udgør herefter kr. 61.897,00.
Kapitalen er opdelt i klasser.
Bestyrelse:
Fratrådte:
Jeppe Ragnar Andersen, den 27.03.2025, Anders Bue Klein, den 27.03.2025, Jonas Odgaard Petersen, den 27.03.2025, Mikael Søndergaard Thomsen, den 27.03.2025, Morten Peltola Toft, den 27.03.2025.
Tiltrådte:
Margareta Elisabeth Björk, den 27.03.2025, Menelas Nicolas Pangalos, den 27.03.2025, Otello Stampacchia, den 27.03.2025.
Selskabet tegnes af bestyrelsesformanden sammen med to bestyrelsesmedlemmer eller af den samlede bestyrelse i forening.
Revision:
Tiltrådte:
CVR-NR. 33771231 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB, Strandvejen 44, 2900 Hellerup, den 27.03.2025.
Vedtægter ændret: 14.02.2023
Bestyrelse:
Tiltrådte:
Jeppe Ragnar Andersen, den 14.02.2023, Christoffer Clemmensen, den 14.02.2023, Anders Bue Klein, den 14.02.2023, Founder Ian Rodney Laquian, (formand), den 14.02.2023, Jonas Odgaard Petersen, den 14.02.2023, Mikael Søndergaard Thomsen, den 14.02.2023, Morten Peltola Toft, den 14.02.2023.
Selskabet tegnes af den samlede bestyrelse i forening eller af den samlede direktion i forening.
Vedtægter ændret: 22.02.2022
Nyt navn: Ousia Pharma ApS
Stiftelsesdato: 14.02.2022.
Virkningsdato: 14.02.2022.
Seneste vedtægtsdato: 14.02.2022.
Kapital:
kr. 40.002,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.002,00 til kurs 100,00, fuldt indbetalt.
Stiftere:
CVR-NR. 42926337 Science Studio Holding ApS, Ligustervænget 57, 2830 Virum, den 14.02.2022, CVR-NR. 42954993 Nordic Alchemy Holding ApS, Egebovej 10, st. th, 2800 Kongens Lyngby, den 14.02.2022, CVR-NR. 43013262 Klein Science Holding ApS, Daltoftevej 11, 2860 Søborg, den 14.02.2022.
Direktion:
Christoffer Clemmensen, den 14.02.2022, Anders Bue Klein, den 14.02.2022, Jonas Odgaard Petersen, den 14.02.2022.
Selskabet tegnes af den samlede direktion
Første regnskabsår:
14.02.2022 - 31.12.2022.
Regnskabsår:
01.01 - 31.12.
Formål:
Formål er at udvikle nye lægemiddelkandidater til behandling af kroniske sygdomme.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
What Pro holds for Ousia Pharma ApS:
Have Pro? Sign in.
P-number 1027996171Ole Maaløes Vej 3, 2200 København N
No other current company drawn.
No other current company drawn.
No other current company drawn.
No other current company drawn.